| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
9-Cyclopentyladenine (CPA) is an adenylyl cyclase inhibitor. [1]
|
|---|---|
| ln Vitro |
9-Cyclopentyladenine monomethanesulfonate (200 μM, 30 min) totally prevents neurogenesis in PC12 cells and suppresses the activation of cAMP response element-binding pigment (CREB) [1]. In the ileum of female CD1 Swiss mice, the effects of 9-cyclopentyladenine monomethane sulfonate (100 μM, 30 min) on mechanorelaxin activity and suppression of mechanorelaxin-induced hypersensitivity[2]. In hairless mice, 9-cyclopentyladenine monomethanesulfonate (100 μM, 6 hours) stimulates cAMP production, which aids in the repair of the duct-forming cell permeability barrier [3].
9-Cyclopentyladenine (CPA) at a concentration of 200 μM significantly decreased the activation of transcription factor CREB induced by Militarinone A (MILI A) in PC12 cells, as assessed by Western blot analysis using a phospho-specific antibody against CREB (Ser133). [1] 9-Cyclopentyladenine (CPA) at 200 μM completely blocked MILI A-induced neuritogenesis in NGF-primed PC12 cells, as observed by phase contrast microscopy. [1] MILI A did not show a direct activating effect on adenylyl cyclase activity in assays with isolated PC12 membranes, in contrast to forskolin, a known activator of adenylyl cyclase. [1] |
| Enzyme Assay |
Adenylyl cyclase activity was assessed in isolated PC12 cell membranes to determine whether MILI A directly activated the enzyme. Membranes were prepared from PC12 cells, and the activity of adenylyl cyclase was measured in the presence of MILI A or forskolin as a positive control. The assay did not indicate any activating effect of MILI A on adenylyl cyclase, suggesting that MILI A’s effect on cAMP levels might be indirect, possibly via membrane interaction. [1]
|
| Cell Assay |
PC12 cells were primed with NGF (50 ng/ml) for 4 days under serum-starved conditions (1% horse serum, 0.5% fetal bovine serum) to enhance TrkA receptor density and sensitivity. Primed cells were then seeded in collagen-coated 24-well plates. After 2 hours of cultivation, cells were pretreated with 9-Cyclopentyladenine (CPA) at 200 μM for 30 minutes, followed by treatment with MILI A (40 μM) for 16–24 hours. Neurite outgrowth was assessed by phase contrast microscopy. CPA completely inhibited MILI A-induced neurite formation, while control cells treated with MILI A alone showed significant neurite outgrowth. [1]
Western blot analysis was performed to evaluate the phosphorylation state of CREB. PC12 cells were serum-starved overnight, pretreated with CPA (200 μM) for 30 minutes, and then exposed to MILI A (10 or 40 μM) for 30 minutes or 24 hours. Cells were lysed, and equal amounts of protein were separated by SDS-PAGE, transferred to PVDF membranes, and probed with phospho-specific antibodies against CREB (Ser133). CPA moderately decreased MILI A-induced CREB phosphorylation. [1] |
| Animal Protocol |
Experiments were performed on 8- to 12-week-old female CD1 Swiss strain mice. Animals were housed under a 12-hour light/dark cycle at a constant temperature of 21 ± 1°C with standard laboratory feed. After one week of acclimatization, the phase of the estrous cycle was assessed by vaginal smear cytology, and only mice in proestrus or estrus (estrogen-dominated phases) were used. Mice were killed by cervical dislocation. The abdomen was opened, and the distal ileum (within 30 mm from the ileocaecal valve) was removed and cleaned with physiological solution. For mechanical experiments, ileal segments (10 mm in length) were mounted in organ baths containing Krebs-Henseleit solution (gassed with 95% O2 / 5% CO2, maintained at 37 ± 0.5°C) under an initial tension of 1.5 g. Isometric tension was recorded. For electrophysiological experiments, ileal strips were prepared by dissecting away mucosa and submucosa, and the smooth muscle layer was pinned in a recording chamber for microelectrode impalement. 9-Cyclopentyladenine Mesylate was dissolved and used at a final bath concentration of 100 µmol/L. [2]
|
| References |
|
| Additional Infomation |
9-Cyclopentyladenine (CPA) is a pharmacological tool used to inhibit the activity of adenylate cyclase in cell studies. [1] The inhibitory effect of CPA in MILI A-induced neurogenesis in PC12 cells suggests that increased cAMP levels and adenylate cyclase activity may be involved in the neurogenesis signaling pathway, possibly through adenosine receptor-coupled regulation or indirect membrane effects. [1] Although CPA only moderately reduced CREB phosphorylation levels, it completely blocked neurogenesis, suggesting that the cAMP-dependent pathway is crucial for MILI A-induced differentiation and is independent of the ERK and PI3K pathways. [1]
|
| Molecular Formula |
C11H17N5O3S
|
|---|---|
| Molecular Weight |
299.34
|
| Exact Mass |
299.105
|
| CAS # |
189639-09-6
|
| PubChem CID |
6604076
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
440.5ºC at 760 mmHg
|
| Melting Point |
180-183ºC(lit.)
|
| Flash Point |
220.2ºC
|
| Vapour Pressure |
5.85E-08mmHg at 25°C
|
| LogP |
2.689
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
320
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AJMDRSJHCYQPQI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13N5.CH4O3S/c11-9-8-10(13-5-12-9)15(6-14-8)7-3-1-2-4-7;1-5(2,3)4/h5-7H,1-4H2,(H2,11,12,13);1H3,(H,2,3,4)
|
| Chemical Name |
9-cyclopentylpurin-6-amine;methanesulfonic acid
|
| Synonyms |
9-CP-Ade Mesylate 9CPAde Mesylate 9 CP Ade Mesylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~139.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3407 mL | 16.7034 mL | 33.4068 mL | |
| 5 mM | 0.6681 mL | 3.3407 mL | 6.6814 mL | |
| 10 mM | 0.3341 mL | 1.6703 mL | 3.3407 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
